Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

5,158 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Effect of denosumab administration on low bone mineral density (T-score -1.0 to -2.5) in postmenopausal Japanese women receiving adjuvant aromatase inhibitors for non-metastatic breast cancer.
Nakatsukasa K, Koyama H, Ouchi Y, Sakaguchi K, Fujita Y, Matsuda T, Kato M, Konishi E, Taguchi T. Nakatsukasa K, et al. Among authors: matsuda t. J Bone Miner Metab. 2018 Nov;36(6):716-722. doi: 10.1007/s00774-017-0884-x. Epub 2017 Nov 7. J Bone Miner Metab. 2018. PMID: 29116414 Clinical Trial.
Effect of denosumab on bone mineral density in Japanese women with osteopenia treated with aromatase inhibitors for breast cancer: subgroup analyses of a Phase II study.
Nakatsukasa K, Koyama H, Ouchi Y, Sakaguchi K, Fujita Y, Matsuda T, Kato M, Konishi E, Taguchi T. Nakatsukasa K, et al. Among authors: matsuda t. Ther Clin Risk Manag. 2018 Jul 10;14:1213-1218. doi: 10.2147/TCRM.S167579. eCollection 2018. Ther Clin Risk Manag. 2018. PMID: 30022834 Free PMC article.
Effect of denosumab on low bone mineral density in postmenopausal Japanese women receiving adjuvant aromatase inhibitors for non-metastatic breast cancer: 24-month results.
Nakatsukasa K, Koyama H, Ouchi Y, Ono H, Sakaguchi K, Matsuda T, Kato M, Ishikawa T, Yamada K, Yoshimura M, Koizumi K, Sakurai T, Shigematsu H, Takahashi S, Taira S, Suzuki M, Narui K, Niikura N, Hasegawa Y, Miura D, Konishi E, Taguchi T; Collaborative Study Group of Scientific Research of the Japanese Breast Cancer Society. Nakatsukasa K, et al. Among authors: matsuda t. Breast Cancer. 2019 Jan;26(1):106-112. doi: 10.1007/s12282-018-0896-y. Epub 2018 Jul 27. Breast Cancer. 2019. PMID: 30054855 Clinical Trial.
Predictive factors for the efficacy of denosumab in postmenopausal Japanese women with non-metastatic breast cancer receiving adjuvant aromatase inhibitors: a combined analysis of two prospective clinical trials.
Nakatsukasa K, Koyama H, Ouchi Y, Sakaguchi K, Fujita Y, Matsuda T, Kato M, Konishi E, Taguchi T. Nakatsukasa K, et al. Among authors: matsuda t. J Bone Miner Metab. 2019 Sep;37(5):864-870. doi: 10.1007/s00774-018-00985-8. Epub 2019 Mar 13. J Bone Miner Metab. 2019. PMID: 30868270 Clinical Trial.
Docetaxel and cyclophosphamide as neoadjuvant chemotherapy in HER2-negative primary breast cancer.
Nakatsukasa K, Koyama H, Oouchi Y, Imanishi S, Mizuta N, Sakaguchi K, Fujita Y, Fujiwara I, Kotani T, Matsuda T, Fukuda K, Morita M, Kawakami S, Kadotani Y, Konishi E, Yanagisawa A, Taguchi T. Nakatsukasa K, et al. Among authors: matsuda t. Breast Cancer. 2017 Jan;24(1):63-68. doi: 10.1007/s12282-016-0666-7. Epub 2016 Jan 11. Breast Cancer. 2017. PMID: 26754092 Clinical Trial.
Docetaxel, cyclophosphamide, and trastuzumab as neoadjuvant chemotherapy for HER2-positive primary breast cancer.
Nakatsukasa K, Koyama H, Oouchi Y, Imanishi S, Mizuta N, Sakaguchi K, Fujita Y, Imai A, Okamoto A, Hamaoka A, Soushi M, Fujiwara I, Kotani T, Matsuda T, Fukuda K, Morita M, Kawakami S, Kadotani Y, Konishi E, Yanagisawa A, Goto M, Yamada K, Taguchi T. Nakatsukasa K, et al. Among authors: matsuda t. Breast Cancer. 2017 Jan;24(1):92-97. doi: 10.1007/s12282-016-0677-4. Epub 2016 Feb 13. Breast Cancer. 2017. PMID: 26874836 Clinical Trial.
Phase II Clinical Trial of First-line Eribulin Plus Trastuzumab for Advanced or Recurrent HER2-positive Breast Cancer.
Sakaguchi K, Nakatsukasa K, Koyama H, Kato M, Sakuyama A, Matsuda T, Tsunoda N, Fujiwara I, Yamaguchi M, Tanaka H, Onishi K, Onishi M, Yoshino Y, Kikuchi T, Taguchi T. Sakaguchi K, et al. Among authors: matsuda t. Anticancer Res. 2018 Jul;38(7):4073-4081. doi: 10.21873/anticanres.12697. Anticancer Res. 2018. PMID: 29970533 Clinical Trial.
5,158 results